These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23083502)

  • 21. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
    Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
    Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu.
    Diallo R; Rody A; Jackisch C; Ting E; Schaefer KL; Kissler S; Karn T; Geddert H; Engels K; Kaufmann M; Gabbert HE; Shroyer KR; Poremba C
    Hum Pathol; 2006 Feb; 37(2):205-11. PubMed ID: 16426921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast.
    Rody A; Diallo R; Poremba C; Speich R; Wuelfing P; Kissler S; Solbach C; Kiesel L; Jackisch C
    Oncol Rep; 2004 Oct; 12(4):695-9. PubMed ID: 15375487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carcinoma In Situ Involving Sclerosing Adenosis on Core Biopsy: Diagnostic Pearls to Aid the Practicing Clinician and Avoid Overtreatment.
    Richards D; Ayala AA; Wu Y; Middleton LP
    Oncol Ther; 2020 Jun; 8(1):81-89. PubMed ID: 32700071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
    Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
    Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiogenic potential of ductal carcinoma in situ (DCIS) of human breast.
    Vogl G; Dietze O; Hauser-Kronberger C
    Histopathology; 2005 Dec; 47(6):617-24. PubMed ID: 16324200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breast carcinoma in situ in 167 women--incidence, mode of presentation, therapy and follow-up.
    Ringberg A; Andersson I; Aspegren K; Linell F
    Eur J Surg Oncol; 1991 Oct; 17(5):466-76. PubMed ID: 1657650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
    Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
    Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening mammography-detected ductal carcinoma in situ: mammographic features based on breast cancer subtypes.
    Kim MY; Kim HS; Choi N; Yang JH; Yoo YB; Park KS
    Clin Imaging; 2015; 39(6):983-6. PubMed ID: 26259866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A clinico-pathological study on cancer in sclerosing adenosis.
    Ogura K; Horii R; Oosako T; Iwase T; Akiyama F
    Breast Cancer; 2014 Nov; 21(6):732-7. PubMed ID: 23408123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Noninvasive carcinoma of the breast presenting in adenosis.
    Oberman HA; Markey BA
    Mod Pathol; 1991 Jan; 4(1):31-5. PubMed ID: 1850517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nudix-type motif 2 in human breast carcinoma: a potent prognostic factor associated with cell proliferation.
    Oka K; Suzuki T; Onodera Y; Miki Y; Takagi K; Nagasaki S; Akahira J; Ishida T; Watanabe M; Hirakawa H; Ohuchi N; Sasano H
    Int J Cancer; 2011 Apr; 128(8):1770-82. PubMed ID: 20533549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinicopathologic features and treatment of ductal carcinoma in situ of the breast].
    Zhou L; Wang Y; Song X; Du JW; Pei F; Huang LP; Wang WY; Liu ZB; Pan RQ
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3035-8. PubMed ID: 16324401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
    Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
    Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical expression of E-cadherin in sclerosing adenosis, ductal carcinoma in situ and invasive ductal carcinoma of the breast.
    Facina G; Lopes-Costa PV; Dos Santos AR; De Vasconcelos-Valença RJ; Pinho-Sobral AL; Ferreira-Filho CP; Alencar AP; Gebrim LH; Da Silva BB
    Diagn Cytopathol; 2010 Apr; 38(4):235-8. PubMed ID: 19790246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical value of contralateral breast cancers detected by pre-operative MRI in patients diagnosed with DCIS: a population-based cohort study.
    Keymeulen KBIM; Geurts SME; Kooreman LFS; Duijm LEM; Engelen S; Vanwetswinkel S; Luiten E; Siesling S; Voogd AC; Tjan-Heijnen VCG
    Eur Radiol; 2023 Mar; 33(3):2209-2217. PubMed ID: 36180645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sonographic findings of pure ductal carcinoma in situ.
    Lee MH; Ko EY; Han BK; Shin JH; Ko ES; Hahn SY
    J Clin Ultrasound; 2013 Oct; 41(8):465-71. PubMed ID: 23949917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ultrasound characteristics of sclerosing adenosis mimicking breast carcinoma.
    Liu W; Li W; Li Z; Shi L; Zhao P; Guo Z; Tian J; Wang Z
    Breast Cancer Res Treat; 2020 May; 181(1):127-134. PubMed ID: 32227257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathologic features of ductal carcinoma in situ in young women with an emphasis on molecular subtype.
    VandenBussche CJ; Elwood H; Cimino-Mathews A; Bittar Z; Illei PB; Warzecha HN
    Hum Pathol; 2013 Nov; 44(11):2487-93. PubMed ID: 24029706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.